Skip to main content

Detail

Thomas Klikovits
Thomas Klikovits

Department of Surgery (Division of Thoracic Surgery)
Position: Doctor-in-training

ORCID: 0000-0003-1012-0404

Keywords

Biomarkers, Pharmacological; Carcinoma, Non-Small-Cell Lung; Mesothelioma; Neoplasm Staging; Thoracic Surgery

Selected publications

  1. Waseda, R. et al., 2017. Trimodality therapy for Pancoast tumors: T4 is not a contraindication to radical surgery. Journal of Surgical Oncology, 116(2), pp.227-235. Available at: http://dx.doi.org/10.1002/jso.24629.
  2. Lohinai, Z. et al., 2017. KRAS-mutation incidence and prognostic value are metastatic site-specific in lung adenocarcinoma: poor prognosis in patients with KRAS mutation and bone metastasis. Scientific Reports, 7, p.39721. Available at: http://dx.doi.org/10.1038/srep39721.
  3. Klikovits, T. et al., 2016. Management of malignant pleural mesothelioma - part 3. Wiener klinische Wochenschrift, 128(17-18), pp.627-634. Available at: http://dx.doi.org/10.1007/s00508-016-1037-2.
  4. Klikovits, T. et al., 2016. Lung transplantation in patients with incidental early stage lung cancer-institutional experience of a high volume center. Clinical Transplantation, 30(8), pp.912-917. Available at: http://dx.doi.org/10.1111/ctr.12764.
  5. Ghanim, B. et al., 2015. Ki67 index is an independent prognostic factor in epithelioid but not in non-epithelioid malignant pleural mesothelioma: a multicenter study. British Journal of Cancer, 112(5), pp.783-792. Available at: http://dx.doi.org/10.1038/bjc.2015.9.